

Innovative approaches for cocaine pharmacotherapy: the case of rimonabant.

Gepubliceerd: 13-05-2008 Laatste bijgewerkt: 13-12-2022

Rimonabant increases the availability of dopamine D2 receptors in the brain's striatal area. This subsequently reduces cocaine craving and decreases relapse in human detoxified cocaine users.

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON20293

Bron

Nationaal Trial Register

Verkorte titel

Cocaine, Dopamine and Rimonabant (CoDoRi)

Aandoening

addiction, cocaine, relapse, dopamine, DA D2 receptor, rimonabant, dopamine, neuro-imaging, SPECT, fMRI

Ondersteuning

Primaire sponsor: Prof. dr. Wim Van den Brink

dr. Jan Booij

dr. Michelle Miller

drs. Cleo Crunelle

Overige ondersteuning: ZonMW / NIDA

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

To assess the changes in DA D2 receptor availability in the striatum after 2 months of rimonabant treatment.

To assess whether rimonabant can decrease cocaine craving and/or impulsivity in human cocaine users.

To assess whether DA D2 receptor availability in the striatum can predict relapse to cocaine abuse in detoxified cocaine users.

Toelichting onderzoek

Achtergrond van het onderzoek

In today's society, cocaine abuse and relapse remains a growing problem. Abstinent cocaine abusers have difficulties staying "clean", and good treatment strategies for preventing relapse to cocaine abuse are lacking. Dopamine receptor availability in the striatum is linked closely to dependence and relapse disorders, and new imaging techniques allow us to investigate these effects.

Our goal is to build knowledge for an evidence-based strategy to reduce relapse in cocaine addicts. To accomplish this, we propose to:

- a) investigate effects of prolonged treatment with rimonabant on the availability of DA D2 receptors in abstinent cocaine addicts using SPECT;
- b) examine the acute and prolonged effects of Rimonabant on impulse control, motivational strength of drug cues, and brain activation patterns of cocaine-addicted patients compared to non-addicted controls (using fMRI and EEG); and,
- c) examine the extent to which these processes predict relapse.

Doel van het onderzoek

Rimonabant increases the availability of dopamine D2 receptors in the brain's striatal area. This subsequently reduces cocaine craving and decreases relapse in human detoxified cocaine users.

Onderzoeksopzet

SPECT will be performed at baseline, and after 2 months of rimonabant/placebo intake.

fMRI will be performed at baseline, after the first intake of rimonabant/placebo and after 2 months of medication intake.

Neuropsychological assessments will be assessed at consequent timepoints throughout the trial.

Onderzoeksproduct en/of interventie

Rimonabant or placebo will be administered for 2 months. [123I]IBZM SPECT will be performed at baseline and at the end of the experiment to assess the prolonged effects of rimonabant on DA D2 receptor availability in vivo. Additionally, fMRI and EEG will be performed at baseline, after the first tablet, and after two months, together with different neuropsychological assessments.

Contactpersonen

Publiek

Academic Medical Center, University of Amsterdam
Amsterdam Institute for Addiction Research
Department of Psychiatry, PB0-436
P.O. Box 75867

Cleo L. Crunelle
Amsterdam 1070 AW
The Netherlands
+31 (0)20 8913763

Wetenschappelijk

Academic Medical Center, University of Amsterdam
Amsterdam Institute for Addiction Research
Department of Psychiatry, PB0-436
P.O. Box 75867

Cleo L. Crunelle
Amsterdam 1070 AW
The Netherlands
+31 (0)20 8913763

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Male, age 18-60 years
2. Current DSM-IV diagnosis of cocaine dependence, but recently detoxified and abstinent
3. Able to provide written informed consent and to comply with all study procedures.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Currently dependent on any substance other than cocaine or nicotine
2. History of depression that could be defined as even a single episode or recurrent episodes of depression, or depression necessitating hospitalization, or history of suicide attempt (see footnote1)
3. Severe neurological or psychiatric disorders (e.g., psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications)
4. Serious medical illnesses
5. Known hypersensitivity or allergy to rimonabant, or receiving chronic therapy with medication that could interact adversely with one of the medications under study, within 30 days prior to randomization
6. Drugs known to influence binding to DA2 receptors, including neuroleptics, and methylphenidate
7. Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment
8. Clinically significant abnormal laboratory values, as measured by the treatment centre
9. Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication
10. Hypersensitivity to Iodine

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Dubbelblind
Controle:	Placebo

Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-09-2008
Aantal proefpersonen:	30
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies	
Datum:	13-05-2008
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1268
NTR-old	NTR1314
Ander register	: MEC 07/301 #08.17.0109
ISRCTN	ISRCTN wordt niet meer aangevraagd

Resultaten

Samenvatting resultaten

N/A